Guoqiang Hua
Overview
Explore the profile of Guoqiang Hua including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lin H, Wang Y, Cheng C, Qian Y, Hao J, Zhang Z, et al.
Cell Regen
. 2023 Jun;
12(1):24.
PMID: 37378693
Intestinal cancer is one of the most frequent and lethal types of cancer. Modeling intestinal cancer using organoids has emerged in the last decade. Human intestinal cancer organoids are physiologically...
12.
Wang Y, Lin H, Zhao L, Hong F, Hao J, Zhang Z, et al.
Cell Regen
. 2023 Jun;
12(1):23.
PMID: 37314549
Organoids have attracted great interest for disease modelling, drug discovery and development, and tissue growth and homeostasis investigations. However, lack of standards for quality control has become a prominent obstacle...
13.
Guan R, Pan M, Xu X, Du L, Rao X, Fu G, et al.
Cell Transplant
. 2023 Jun;
32:9636897231177377.
PMID: 37291802
Epithelial regeneration is critical for barrier maintenance and organ function after intestinal radiation injury. Accumulating evidence indicates that the interleukin family members play critical roles in intestinal stem-cell-mediated epithelial regeneration....
14.
He X, Jiang Y, Zhang L, Li Y, Hu X, Hua G, et al.
Front Bioeng Biotechnol
. 2023 Jun;
11:1190637.
PMID: 37284236
Most advanced colorectal cancers are aggressive, and there is a lack of effective methods for selecting appropriate anticancer regimens. Patient-derived organoids (PDOs) have emerged as preclinical platforms for modeling clinical...
15.
Mu P, Zhou S, Lv T, Xia F, Shen L, Wan J, et al.
J Exp Clin Cancer Res
. 2023 Apr;
42(1):81.
PMID: 37016422
Immunotherapy as a rapidly developing therapeutic approach has revolutionized cancer treatment and revitalized the field of tumor immunology research. 3D in vitro models are emerging as powerful tools considering their...
16.
Li H, Kucharavy H, Hajj C, Zhao L, Hua G, Glass R, et al.
Cell Death Discov
. 2023 Mar;
9(1):99.
PMID: 36941253
No abstract available.
17.
Li H, Kucharavy H, Hajj C, Zhao L, Hua G, Glass R, et al.
Cell Death Discov
. 2023 Jan;
9(1):31.
PMID: 36697383
Previous studies show increased sensitivity of older mice (28-29 months) compared with young adult mice (3 months, possessing a mature immune system) to radiation-induced GI lethality. Age-dependent lethality was associated...
18.
Weng W, Meng T, Zhao Q, Shen Y, Fu G, Shi J, et al.
Cancer Discov
. 2023 Jan;
13(4):950-973.
PMID: 36693125
Significance: ADCs combining a novel self-immolative moiety and topoisomerase I inhibitor exatecan as payload show deep and durable response in low-target-expressing and MDR+ tumors resistant to DXd/SN-38 ADCs without increasing...
19.
Lv T, Shen L, Xu X, Yao Y, Mu P, Zhang H, et al.
Int J Cancer
. 2022 Sep;
152(3):524-535.
PMID: 36161653
Adding irinotecan to neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) increases the pathologic complete response (pCR) rate but brings more toxicities. Robust biomarkers to predict response to irinotecan-based...
20.
Mo S, Tang P, Luo W, Zhang L, Li Y, Hu X, et al.
Adv Sci (Weinh)
. 2022 Sep;
9(31):e2204097.
PMID: 36058001
There is no effective method to predict chemotherapy response and postoperative prognosis of colorectal cancer liver metastasis (CRLM) patients. Patient-derived organoid (PDO) has become an important preclinical model. Herein, a...